{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:11:07Z","timestamp":1768479067406,"version":"3.49.0"},"reference-count":0,"publisher":"Termedia Sp. z.o.o.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"abstract":"Introduction<\/jats:title>The phase IIIb open-label ODYSSEY APPRISE study prospectively assessed the safety and efficacy of alirocumab (a proprotein convertase subtilisin\/kexin type 9 [PCSK9] inhibitor) in a real-life setting in high cardiovascular risk patients with heterozygous familial hypercholesterolemia or low-density lipoprotein cholesterol (LDL-C) not at goal despite maximally tolerated dose statins \u00b1 other lipid-lowering therapies (NCT02476006). This post-hoc analysis assessed patient adherence to statins and alirocumab, plus alirocumab efficacy and safety, according to concomitant statin intensity and prior ezetimibe usage.<\/jats:p><\/jats:sec>Material and methods<\/jats:title>Patients received alirocumab 75 or 150 mg (dose adjustment based on physician\u2019s judgment) every 2 weeks (for \u22653 to \u226430 months).<\/jats:p><\/jats:sec>Results<\/jats:title>Of 994 enrolled and treated patients, 58.4% received concomitant high-intensity statins, 18.2% moderate\/low-intensity statins, and 23.4% no statin; 55.9% received prior ezetimibe. Mean alirocumab adherence (percent adherence defined as injections received \u00f7 theoretical injections x 100) was 96.6% over 72.4 weeks\u2019 mean treatment duration. Mean LDL-C reduction from baseline at Week 12 was similar between statin intensity subgroups (53.6\u201355.7%). More patients achieved LDL-C <1.8 mmol\/L and\/or \u226550% reduction from baseline in the \u2265100% versus <100% adherent to alirocumab subgroup; high-intensity and low\/moderate-intensity subgroups versus no statin subgroup; and prior ezetimibe versus no prior ezetimibe subgroup. Treatment-emergent adverse events occurred in 65.2\u201375.1% and 68.0\u201376.3% of patients across statin and ezetimibe subgroups, respectively.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>In a real-life setting, patient adherence to alirocumab was high. Alirocumab provided clinically significant reductions in LDL-C, with most patients achieving LDL-C treatment targets across background statin therapy and prior ezetimibe therapy subgroups.<\/jats:p><\/jats:sec>","DOI":"10.5114\/aoms\/143476","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:12:48Z","timestamp":1645834368000},"page":"285-292","source":"Crossref","is-referenced-by-count":15,"title":["Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE"],"prefix":"10.5114","volume":"18","author":[{"given":"Maciej","family":"Banach","sequence":"first","affiliation":[{"name":"Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"L\u00f3pez-Sendon","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, IdiPaz, CIBER-CV, UAM, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[{"name":"Department of Health Promotion Sciences, Maternal and Infantile Care, Internal Medicine and Medical Specialties \u2013 PROMISE, School of Medicine, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"l\u2019institut du thorax, CHU Nantes, INSERM, CNRS, UNIV Nantes, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Loy","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, NJ, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabela","family":"Batsu","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, NJ, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Poulouin","sequence":"additional","affiliation":[{"name":"IT&M Stats, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"ECOGENE-21 and Clinical Lipidology Unit, Community Gene Medicine Center, Department of Medicine, Universit\u00e9 de Montr\u00e9al, Chicoutimi, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2021,10,29]]},"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-143476-72821","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-143476-72821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:12:48Z","timestamp":1645834368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/Treatment-adherence-and-effect-of-concurrent-statin-intensity-on-the-efficacy-and,143476,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"alternative-id":["143476"],"URL":"https:\/\/doi.org\/10.5114\/aoms\/143476","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"value":"1734-1922","type":"print"},{"value":"1896-9151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]}}}